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http://dx.doi.org/10.1016/j.ccr.2013.12.009SUMMARYWedefine the activity andmechanisms of action of a small molecule lead compound for cancer targeting.We
show that the compound, BMH-21, has wide and potent antitumorigenic activity across NCI60 cancer cell
lines and represses tumor growth in vivo. BMH-21 binds GC-rich sequences, which are present at a high fre-
quency in ribosomal DNA genes, and potently and rapidly represses RNA polymerase I (Pol I) transcription.
Strikingly, we find that BMH-21 causes proteasome-dependent destruction of RPA194, the large catalytic
subunit protein of Pol I holocomplex, and this correlates with cancer cell killing. Our results show that Pol I
activity is under proteasome-mediated control, which reveals an unexpected therapeutic opportunity.INTRODUCTION
Major efforts are currently invested in large-scale cancer
genome sequencing projects for the identification of cancer-
specific alterations and to apply this information to diagnostics,
tumor classification, and therapeutic exploitation. Specifically,
the cancer genome mutational analyses pinpointed pathways
that are frequently deregulated and highlighted key mutational
events based on which new therapeutic molecules have been
successfully devised (Stratton, 2011; Vogelstein et al., 2013).
However, the application of the targeted therapies has also
revealed the robustness of the cancer cell circuitries to over-
come the repression thus inflicted and suggested that further
cancer-relevant pathways or combinatory therapies need to be
identified. The cancer cell circuitries support complex cellular
characteristics that in addition to mutational events are altered
by epigenetic changes and alterations in cellular metabolic rates
and affected by the nonphysiological cues that cancer cells are
exposed to. In particular, the cancer cells mustmeet the demandSignificance
Pol I is a large transcriptional holocomplex that governs the pro
rate, is robust, and responds to extracellular cues. Pol I activity
and/or tumor suppressor inactivation. Despite the key importa
been directed to its therapeutic targeting. The data presented
protein component. The findings strongly support that therap
feasible and rational approach.for the increase in protein synthetic rates due their increased
biosynthetic activities, high division rates, and proteotoxicity
that results from protein misfolding (Luo et al., 2009; Whitesell
and Lindquist, 2009). These needs are met by increases in pro-
tein synthetic and translation rates.
Ribosome biogenesis is a unique process of the nucleolus.
This is a multistep process that entails ribosomal (r) RNA
transcription, maturation of pre-rRNA transcripts, assembly of
preribosomal particles, and late RNA processing (Fatica and
Tollervey, 2002; Leary and Huang, 2001). These activities are
specified by distinct groups of proteins and RNA, which partici-
pate in the key output of the nucleolus—synthesis of the 60S and
40S ribosomal subunits. rDNA is transcribed by RNApolymerase
I (Pol I) to a long 47S rRNA precursor and processed through
multiple steps to the 18S, 5.8S, and 28S mature rRNAs (Comai,
2004; Haag and Pikaard, 2007; Russell and Zomerdijk, 2006).
rDNA is the most highly transcribed region of the eukaryotic
genome, andmore than 60%of total cellular transcription results
from Pol I activity. rDNA is a multicopy gene with interspersedduction of ribosomal RNA. Pol I transcription occurs at a high
is frequently deregulated in cancers by oncogene activation
nce of Pol I activity to cancer cells, only limited efforts have
here identify a potent small molecule acting on a key Pol I
eutic exploitation of deregulated Pol I activity in cancer is a
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Pol I Targeting by a Small Molecule Compoundactive and inactive gene repeats (McStay and Grummt, 2008).
rRNA synthesis is controlled by changing the rate of transcription
of individual repeats, or the number of active genes (Grummt,
2010; Russell and Zomerdijk, 2006). The latter is under epige-
netic regulation and observed during development and differen-
tiation, whereas the former is evident during regulation of cell
growth by external signals (Grummt, 2010; McStay and Grummt,
2008). Strikingly, the active rDNA genes are in an open chromatin
conformation and nucleosome-free (Merz et al., 2008; Wittner
et al., 2011). rDNA transcription is initiated by formation of the
preinitiation complex by the promoter selectivity factor, termed
as SL1 and upstream binding factor (UBF; Comai, 2004; Haag
and Pikaard 2007; Russell and Zomerdijk, 2006). UBF associa-
tion with rDNA facilitates DNA bending to nucleosome-like struc-
tures and recruits the Pol I holocomplex (Sanij and Hannan,
2009). The Pol I holocomplex is composed of 14 subunits in eu-
karyotes, two of which are unique, five share limited sequence
conservation with RNA polymerase II (Pol II), and the remainder
are shared between RNA polymerases I, II, and III (Kuhn et al.,
2007; Lane et al., 2011). Pol I occupies rDNA at high density. In
yeast, Pol I complex is present at 100 base pair (bp) intervals
throughout most of the rDNA. Topologically, the rDNA transcrip-
tion may take place around a centrally located initiation core sur-
rounded by a helical cylinder of the elongating Pol I complexes
(Denissov et al., 2011). Hence, destabilization of the rDNA helix,
or loss of the protein framework, will effectively stall transcrip-
tion. The interaction between RPA194 and RPA135, the two
largest proteins in Pol I complex, is considered highly stable,
and RPA194 forms several holocomplexes (Lane et al., 2011).
Nucleolar activities are increased in cancer, and mutations of
nucleolar and ribosomal proteins drive tumorigenesis (Monta-
naro et al., 2008; Pederson, 2011; Ruggero and Pandolfi,
2003). rRNA synthesis is commonly deregulated in cancer, by
overt activation by oncogenes, like Myc, Her2/Neu; growth fac-
tor signaling pathways, e.g., through mTOR, ERK, Akt/PKB; or
loss of tumor suppressor activity, like p53, pRB, ARF, AMPK,
or PTEN (Arabi et al., 2005; Budde and Grummt, 1999; Cava-
naugh et al., 1995; Chan et al., 2011; Hoppe et al., 2009; Li
et al., 2011; Mayer et al., 2004; Schlosser et al., 2003; Sugimoto
et al., 2003; Zhai and Comai, 2000). In addition, the high level of
rRNA synthetic activity is reflected by increased nucleolar size
and prominence in most cancer cells, indicating a possible
global requirement for increased ribosynthetic activity to meet
their increased protein synthesis demands. Pathological
stresses that abrogate Pol I transcription lead to rapid nucleolar
reorganization characterized by segregation of nucleolar sub-
structures (Hernandez-Verdun, 2006) and are profound signals
leading to the activation of p53 (Boulon et al., 2010; Kurki
et al., 2004; Rubbi and Milner, 2003; Zhang and Lu, 2009).
Inhibition of Pol I has been minimally exploited in the clinic.
Actinomycin D (ActD) is a known Pol I inhibitor in clinical use,
but has pleiotropic effects on both DNA and RNA, causes DNA
damage and is encumbered by high toxicity that limits its use
(Harris, 1976). Recently, an rRNA biosynthesis-targeting
compound (CX-5461) has been described that reduces the
engagement of SL1 preinitiation complex to rDNA and conveys
antitumorigenic activity in p53-dependent manner in vitro and
in vivo (Bywater et al., 2012; Drygin et al., 2011). A recent survey
of impact of chemotherapeutic drugs on rRNA biogenesis indi-78 Cancer Cell 25, 77–90, January 13, 2014 ª2014 Elsevier Inc.cated that many inhibited rRNA biosynthesis, suggesting that
this activity could contribute to their overall efficacy (Burger
et al., 2010). Notably, all cause extensive DNA damage. Because
most growth-promoting signals converge to hyperactivate Pol I
transcription, specific inhibition of its activity presents an excep-
tional therapeutic opportunity (Bywater et al., 2013; Grummt,
2010).
Here we provide detailed characterization of the activity of a
small molecule compound, BMH-21, that we discovered in a
large-scale cell-based high-content screen (Peltonen et al.,
2010). BMH-21 is a potent activator of the p53 pathway and in-
tercalates with DNA, but was strikingly identified as a compound
that did not activate the cellular DNA damage response, and the
mechanism whereby it elicited its activity remained unclear (Pel-
tonen et al., 2010). The goal of this studywas to provide evidence
of its antitumorigenic activity and to identify its mechanism of
action.
RESULTS
BMH-21 Is a Potent Anticancer Small Molecule that Acts
Independently of p53
We identified BMH-21 in a cell-based high-throughput screen of
synthetic chemical libraries using p53 transcriptional activation
as readout (Peltonen et al., 2010). We subjected BMH-21 to
the NCI Developmental Therapeutics Program NCI60 cancer
screen (Shoemaker, 2006). BMH-21 showed growth inhibition
in a broad range of cancer cell lines with a mean half-maximal
inhibition of cell proliferation (GI50) of 160 nM (Figure 1A;
Figure S1A available online). Further, COMPARE analysis ( Shoe-
maker, 2006) indicated that the BMH-21 response profile was
unique (not shown). BMH-21 had more than 90-fold therapeutic
window as compared to normal cell responses (Figure 1B; Pelto-
nen et al., 2010). Despite that BMH-21 was originally identified in
a screen for wild-type p53 activation, we observed potent
growth repression also in TP53 null and mutant cell lines (GI50
110 and 205 nM inwild-type andmutant TP53 cells, respectively,
Figure 1C). This indicated that although BMH-21 activates p53, it
acts also upstream of p53 on other, potentially highly growth
restrictive pathways.
Cellular growth and viability assays revealed that BMH-21
potently inhibited DNA replication and increased cell death as
shown by multiparameter flow cytometry (Figures 1D–1F).
BMH-21 also demonstrated potent antitumor activity at
25 mg/kg and 50 mg/kg in a human melanoma xenograft model
and reduced Ki67 proliferation index (Figure 1G). Similarly, BMH-
21 significantly inhibited HCT116 colon cancer tumor growth
(Figure 1H). The tumor control ratios, calculated as change of
median tumor weight over the course of treatment in the treat-
ment group as compared to the control group, were 21% and
30% for the A375 and HCT116 xenografts, respectively. BMH-
21 did not cause changes in the weight of the mice or organ his-
tology, indicating that it is well tolerated (Figures S1B and S1C).
BMH-21 Binds GC-Rich DNA
BMH-21 is a DNA intercalator, but lacks the common property of
intercalators to cause DNA damage (Peltonen et al., 2010). To
further assess its interaction with DNA, we tested whether it dis-
plays binding toward specific DNA sequences using random
Figure 1. BMH-21 Inhibits Replication and Viability of Cancer Cells In Vitro and Tumor Growth In Vivo
(A) NCI Developmental Therapeutics Program NCI60 screen where 100% represents growth in control cultures and 0% represents initial plating density.
(B) Box plot of IC50 values of BMH-21 in NCI60 cell lines and normal human primary cells (as adopted from Peltonen et al., 2010).
(C) Box plot of GI50 values of TP53 wild-type and mutant cell lines in the NCI60 panel.
(D–F) Flow cytometry analysis of A375 melanoma cells treated with BMH-21 (0.5 mM) for 24 hr. Replicating cells were labeled with 5-BrdU (S). (D) Representative
experiment is shown. (E) Cell cycle distribution of data in (D). The mean (n = 2) and SD are shown. ns, not significant; *p < 0.05. (F) SaOS-2 osteosarcoma cells
treated with BMH-21 (1 mM) for 72 hr. The percentage of cells in sub-G1 is shown.
(G and H) Tumor xenografts. (G) A375 melanoma xenograft assay. BMH-21 was injected intraperitoneally on a cycle 6 days on, 1 day off at the indicated doses.
Inset: after the treatments, tumors were stained for Ki67. Scale bar, 50 mm. (H) HCT116 colorectal carcinoma xenograft assay. Mice were treated daily with 50mg/
kg BMH-21. Treatments were initiated on established tumors 8–13 days postimplantation. The p values were determined using two-way ANOVA. Error bars ±
SEM. ****p < 0.0001.
See also Figure S1.
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ment (FID) assay (Tse and Boger, 2005). A close analog of the
compound, BMH-21a1, was used in several subsequent assays
as control (Figure 2A). BMH-21 showed preferential binding to
GC-rich sequences, whereas BMH-21a1 did not (Figure 2B).
BMH-21 and its analog are distinguished by a nitrogen group
protonated at physiological pH present in the parent, but not
the analog compound. This N-group conveys a significant differ-
ence in charge of the two molecules. To further explore their
characteristics, we performedmolecular modeling of protonated
BMH-21 with a DNA hexamer using Autodock (Trott and Olson,
2010). This revealed stacking of the heteroaromatic ring between
GC-pairs and potential interaction of its N,N-dimethylamino
group with the DNA phosphate backbone (Figure 2C, left). How-ever, BMH-21a1 adopted a strikingly different configuration and
lacked interaction with the DNA backbone (Figure 2C, right).
Comparison of the biological activities of the compounds in
p53-activation assays showed that BMH-21a1 was inactive in
this regard (Figure 2D). This led us to hypothesize that BMH-21
activity is conveyed by its interaction with the DNA backbone
in GC-rich DNA sequences.
We then sought to identify genomic DNA (1) that is GC rich, (2)
the alteration of which may impair cellular viability, and (3) that
conveys activities relevant in nongenotoxic p53 activation. For
this purpose, we tested the GC content and GC-tract length of
BMH-21-regulated genes identified in our earlier study (Peltonen
et al., 2010). Therewas no obvious bias of highGCcontent corre-
lating with gene downregulation by BMH-21 (Figures S2A–S2C).Cancer Cell 25, 77–90, January 13, 2014 ª2014 Elsevier Inc. 79
Figure 2. Binding and Modeling of BMH-21
with GC-Rich DNA
(A) Structures of BMH-21 and BMH-21a1.
(B) FID assay of BMH-21 and BMH-21a1 using
random deoxyoligonucleotide hairpins. Data are
displayed in ranking order and median values of
triplicates are shown.
(C) Molecular modeling of protonated BMH-21
(left) and BMH-21a1 (right) with DNA hexamer
(PDB ID 1Z3F) using Autodock 4.2. C, cytosine; G,
guanine.
(D) p53 western blotting analysis. U2OS cells were
treated with BMH-21 (1 mM) or BMH-21a1 (1 mM)
for 8 hr.
See also Figure S2.
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We then considered other transcriptional programs. Noting that
rDNA is highly GC rich (68% as compared to 42% in human
genome, Figure 3A), that the actively transcribed rDNA genes
are maintained in open chromatin conformation, and are consid-
ered nucleosome-free (Merz et al., 2008; Wittner et al., 2011), we
predicted that rDNA and Pol I transcription in particular could be
affected by BMH-21. Using the FID assay, we assessed the
binding of BMH-21 to multiple hairpin oligonucleotides derived
from the rDNA sequence (Figures 3B and 3C). BMH-21 effec-
tively bound rDNA sequences in vitro in a manner that highly
correlated with their GC content (Figure 3C). To test whether
BMH-21 binding to rDNA affects Pol I activity, we carried out80 Cancer Cell 25, 77–90, January 13, 2014 ª2014 Elsevier Inc.an in vitro Pol I transcription assay.
BMH-21 markedly inhibited Pol I in vitro
transcription similar to ActD (Figure 3D).
BMH-21 Inhibits Potently Pol I
Transcription and Causes
Disintegration of the Nucleolus
To determine whether BMH-21 affects
cellular Pol I transcription, we examined
its effect on rRNA synthesis using several
uridine incorporation assays and by
determining short-lived 50 external tran-
scribed spacer (50ETS) rRNA of the 47S
pre-RNA by qPCR. Cells were treated
with BMH-21 (1 mM) for 3 hr. BMH-21
potently decreased 5-ethynyl uridine
(EU) incorporation and repressed the
expression of 50ETS rRNA (Figures 4A
and 4B). We then used rRNA metabolic
labeling with 3H-uridine and found potent
inhibition of the expression of 47S rRNA
transcript at half-maximal inhibition con-
centration (IC50) 60 nM (Figures 4C and
4D). Metabolic labeling followed by chase
indicated that BMH-21 blocks transcrip-
tion of the rRNA precursor without
affecting rRNA maturation (Figure 4E).
A cellular hallmark of rRNA transcrip-
tion block is the disruption of the nucle-
olar structure and alterations in nucleolarprotein localization and dynamics (Boulon et al., 2010; Hernan-
dez-Verdun, 2006; Pederson, 2011). In line with this we observed
BMH-21-mediated segregation of nucleolar structures and
altered localization of nucleolar proteins (Figure 4F). These
included nucleolar cap formation by fibrillar center proteins
upstream binding factor (UBF) and fibrillarin (FBL), and translo-
cation of granular component proteins nucleophosmin (NPM)
and nucleolin (NCL) to nucleoplasm, whereas their protein levels
remained unaltered (Figures 4F and 4G). Alterations in localiza-
tion but not expression of several nucleolar proteins (AATF,
DDX56, nucleostemin, PES, SENP3) were similarly observed
(Figures S3A and S3B).Withdrawal of BMH-21 2 hr after its appli-
cation on cells showed that these nucleolar effects were fully
Figure 3. BMH-21 Binds rDNA Sequences
in a GC Content-Dependent Manner and
Inhibits rRNA Synthesis In Vitro
(A) rDNA GC-content (top). Red line displays
average human genomic DNA GC-content. Lo-
cations of randomly picked deoxyoligonucleotides
used in the FID assay and rDNA domains are
shown (bottom, blue dots).
(B) FID assay of BMH-21 using rDNA deoxy-
oligonucleotides. EtBr represents 100%. The
mean (n = 3) and SD are shown. The location of
sequences and rDNA domains are shown.
Numbering according to GenBank ID U13369.
(C) Correlation of rDNA sequence GC content to
fluorescence displacement by BMH-21. Pearson
correlation coefficient r = 0.963.
(D) In vitro Pol I transcription assay. HeLa nuclear
extract was mixed with Pol I promoter (pHrP2)
plasmid, BMH-21 or ActD, and in vitro transcrip-
tion product was detected by RT-PCR. The mean
(n = 2) and SEM are shown. Controls include full
transcription reaction (ctrl), omission of nuclear
extract (no extract ctrl), and full reaction with
omission of PCR primers (neg. PCR ctrl).
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BMH-21 causes profound inhibition of rRNA synthesis and leads
to the segregation of the nucleolus.
BMH-21 Causes Loss of Pol I Catalytic Subunit RPA194
and Disassembly of Pol I from rDNA
Pol I transcription is driven by the stochastic assembly of the
preinitiation complex and Pol I holocomplex to rDNA (Gorski
et al., 2008; Hager et al., 2009). Inhibition of transcription leads
to Pol I preinitiation and holocomplex protein reorganization,
but their expression is invariable (Lane et al., 2011). We analyzed
the effect of BMH-21 and ActD as control on Pol I complex
proteins. ActD caused nucleolar cap formation of RPA194, the
large catalytic subunit of Pol I holocomplex (Figure 5A). Un-
expectedly, BMH-21 strongly decreased the staining intensity
of RPA194 (Figure 5A). As determined by Western blotting,
BMH-21 remarkably decreased RPA194 expression, and to a
lesser extent, that of RPA135 (Figure 5B). However, it did not
affect Pol I preinitiation complex proteins TAFI110, TIF-IA, and
UBF, or Pol I holocomplex proteins RPA43 and PAF53 (Figures
5B and 5C and not shown). Chromatin-IP (ChIP) analysis for
RPA194 and RPA135 showed that their association with rDNA
was affected throughout the rDNA gene following BMH-21-treat-
ment, and also led to dissociation of UBF from rDNA (Figure 5D).
As controls, we tested whether BMH-21 affected the binding of
RPA194 to genomic DNA or the binding of histone H3 to genomic
DNAand rDNA. BMH-21 had onlyminor effects on these (Figures
S4A–S4E). These results suggest that BMH-21-activated loss of
RPA194 leads to disassembly of Pol I holocomplex from the
rDNA.
We then compared the activities of BMH-21 and BMH-21a1.
BMH-21 abrogated 5-fluorouridine (FUrd) incorporation whereasCancer Cell 25, 77–9BMH-21a1 had no effect (Figure S4F). In
addition, BMH-21a1 did not affect nucle-
olar protein localizations or expression ofRPA194 (Figures S4G and S4H). In addition, BMH-21a1 did not
alter RPA194 engagement with rDNA as analyzed by ChIP (Fig-
ure S4I) or affect cell viability (Figure S4J). We conclude that
BMH-21a1 represents an inactive analog of BMH-21 and ascribe
this difference to the charge and interaction of the molecules
with GC-rich DNA (Figure 2).
Experiments testing temporal changes of rRNA transcription
and nucleolar integrity by BMH-21 showed that it abrogated
nascent RNA synthesis within 15 min application to cells
(Figure 5E) and led to noticeable translocation of NCL within
30 min (Figure 5F). RPA194 was initially (at 1 hr) observed
in nucleolar caps, and its degradation, as measured by both
western and immunofluorescence analyses, was effected
2–3 hr after BMH-21 application (Figures 5F–5H). These tempo-
ral relationships suggest that inhibition of rRNA transcription is
an imminent response to BMH-21 treatment of cells, followed
by segregation of the nucleolus and loss of RPA194.
Decrease in RPA194Correlateswith Loss of Cancer Cell
Survival
We observed that the effect of BMH-21 on RPA194 degradation
was variable between different cell lines. For example, RPA194
expression was decreased markedly in U2OS cells, whereas it
was unaffected in RPMI-7951 cells (Figure 6A). We analyzed
the effect of BMH-21 on ten melanoma, osteosarcoma, breast,
lung, and colon carcinoma cell lines and measured RPA194
expression. BMH-21 decreased RPA194 to a variable degree
in the cancer cell lines (Figure S5A). The ability of BMH-21 to
cause RPA194 degradation was independent of TP53 genetic
status in the cancer cell lines and in TP53 isogenic HCT116 cells
(Figures S5A and S5B). BMH-21 did not affect the expression of
RPA194 in normal fibroblasts (Figure 6B). Cell lines that were0, January 13, 2014 ª2014 Elsevier Inc. 81
Figure 4. BMH-21 Represses rRNA Synthesis and Causes Segregation of Nucleolar Proteins
(A) A375 cells were treated with BMH-21 (1 mM) for 3 hr and de novo rRNA synthesis wasmeasured using EU labeling and quantified. Themean (n = 2) and SD are
shown.
(B) A375 cells were treated with BMH-21 (1 mM) for 3 hr and rDNA transcription was analyzed by qPCR using three primer sets for short-lived 50ETS rRNA. The
mean (n = 3) and SD are shown. The p value is indicated.
(C and D) Metabolic labeling using 3H-uridine. A375 cells were treated with BMH-21 at concentrations shown for 4 hr and labeled for the last 2 hr. Total RNA was
resolved by electrophoresis and de novo synthesized rRNA was detected using autoradiography. Total 18S rRNA indicates loading. (D) Quantification of 47S
rRNA precursor. The mean (n = 2) and ± SD are shown.
(E) 3H-uridine pulse chase assay. A375 cells were labeled for 30min with 3H-uridine, and washed and incubated for the indicated times with BMH-21 (1 mM). RNA
was isolated and analyzed with agarose gel electrophoresis.
(F and G) A375 cells were treated with BMH-21 (1 mM) for 3 hr and stained for UBF, FBL, NPM, and NCL. Arrowheads indicate nucleolar caps and asterisks
indicate nucleoplasmic translocation. Scale bars, 10 mm. (G) Western blotting analyses of respective proteins.
See also Figure S3.
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nucleolar stress as shown by formation of the cap structures
and NCL translocation (Figures 6C, 6D, and S5C). Accordingly,
BMH-21 inhibited rRNA synthesis in all cancer cell lines as
determined by EU incorporation although the extent of inhibition
varied (Figure S5D).
To query the associations between rRNA synthesis, RPA194
degradation and cancer cell viability we determined the Pearson
correlation coefficient (r). The ability of BMH-21 to decrease cell82 Cancer Cell 25, 77–90, January 13, 2014 ª2014 Elsevier Inc.viability moderately associated with high basal rRNA synthetic
activity (r = 0.492; Figure S5E) and its ability to repress
EU incorporation (r = 0.471; Figure 6E) in the cancer cell lines.
Strikingly, the BMH-21-mediated decrease of RPA194 showed
very strong association with reduced cancer cell viability (r =
0.882; Figure 6F).
To further address the relevance of RPA194 for cell viability,
we silenced RPA194 expression using RNAi. Effective RPA194
depletion was demonstrated by western blotting and inhibition
Figure 5. BMH-21 Causes Destruction of RPA194
(A) A375 cells were treated with BMH-21 (1 mM) or ActD (50 ng/ml) for 3 hr and stained for RPA194 and NCL. Merged image with DNA staining is shown below.
Scale bar, 10 mm.
(B and C) Western blotting of lysates fromBMH-21-treated A375 cells (1 mM, 3 hr) for (B) RPA194, RPA135, TIF-IA, and SL1 protein TAFI110 and (C) Pol I complex
proteins RPA43 and PAF53.
(D) ChIP analyses of RPA194, RPA135 and UBF binding to rDNA of A375 cells mock-treated (DMSO, blue bars) or treated with BMH-21 (1 mM; red bars) for 3 hr.
The mean (n = 3) and SEM are shown. Primer locations based on GenBank ID U13369 are shown below.
(E and F) Kinetics of the nucleolar responses. A375 cells were treated with BMH-21 (1 mM) for times shown. (E) Cotreatment of cells with FUrd, and detection of
FUrd incorporation. a-Amanitin (2 mM) was used to control Pol II-mediated transcription. (F) Staining for RPA194, green; NCL, red; and DNA, blue. Arrowheads,
cap structures. Scale bars, 10 mm.
(G andH) RPA194 half-life analyses. (G) A375 cells were treatedwith cycloheximide in the presence or absence of BMH-21 (1 mM) for the indicated times. RPA194
was detected using western blotting. NCL, loading control. Representative experiment is shown. (H) Quantification of RPA194 half-life. CHX, cycloheximide. n = 7
independent experiments. Error bars, SD.
See also Figure S4.
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by siRNA decreased cancer cell growth and viability (Figures 6G
and 6H). These findings suggested that the basal transcription
rates and the ability of BMH-21 to repress rRNA synthesis
were associated with loss of cell viability. Moreover, the degra-
dation of RPA194 showed striking association with the cellular
outcome.
Inhibition of RPA194 Degradation Does Not Rescue Pol I
Transcription
BMH-21 did not affect the expression RPA194 (POLR1A) tran-
script (Figure S6A), excluding that the loss of RPA194 results
from its decreased transcription. In accordance to reversibility
of the nucleolar stress response following washing off BMH-21(Figure S3C), the expression of RPA194 was regained and
the cells resumed rRNA synthesis when depleted of BMH-21
(Figures S6B and S6C). The decrease in RPA194 half-life (Fig-
ure 5H) by BMH-21 suggested that RPA194 expression could
be controlled by the ubiquitin-proteasome system. Accordingly,
treatment of cells with proteasome inhibitors MG132 and lacta-
cystin led to retention of RPA194 in the nucleolar caps and
decreased RPA194 degradation (Figures 7A and 7B). However,
inhibition of RPA194 degradation by MG132 did not rescue
rRNA transcription as shown by rRNA metabolic labeling and
FUrd incorporation experiments (Figures 7C and 7D). Attempts
to assess whether stabilization of RPA194 would desensitize
the cells to BMH-21-mediated cell killing were unsuccessful
due to extensive toxicity of MG132 during long-term treatmentsCancer Cell 25, 77–90, January 13, 2014 ª2014 Elsevier Inc. 83
Figure 6. Loss of RPA194 Correlates with
Decreased Cancer Cell Viability
(A) U2OS and RPMI-7951 cells were treated with
BMH-21 (1 mM) and ActD (50 ng/ml) for indicated
times. Representative western blots for RPA194
and NCL.
(B) WS-1 normal human diploid fibroblasts were
incubated with BMH-21 (1 mM) or ActD (50 ng/ml)
for the indicated times.
(C and D) WS-1 normal fibroblasts (C) and RPMI-
7951 melanoma cells (D) were treated with BMH-
21 (1 mM) for 8 and 6 hr, respectively, and stained
for the indicated proteins. Arrowheads, cap
structures. Scale bars, 10 mm.
(E) Correlation analysis of viability and nascent
rRNA synthesis. Cells were treated with BMH-21
(1 mM) for 3 hr and incubated for the last 1 hr
with EU. Fold change in EU incorporation is
plotted. Data represent mean of n = 2. Cell
viability was assessed using WST-1 assay
following 24 hr treatment with BMH-21. The mean
of n = 3 are shown. Pearson correlation coefficient
r = 0.471.
(F) Cancer cell line responses to BMH-21. Cells
were treated with BMH-21 (1 mM) for 3 hr and
RPA194 was quantified from western blots. Cell
viability was assessed using WST-1 assay after
24 hr treatment. Data represents mean of n = 3
biological repeats for each approach. Pearson
correlation coefficient r = 0.882.
(G and H) Cell viability and growth in RPA194-
depleted cells. U2OS cells were transfected with
control (si ctrl) or two different RPA194 targeting
RNAi duplexes (si403, si405). Cells were incu-
bated for 48 hr and cell numbers were counted (G)
or for 72 hr and cell viability was determined by
WST-1 assay (H). n = 2–3, error bars represent SD.
**p < 0.01, ***p < 0.001.
See also Figure S5.
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caps represent stalled transcription sites.
RPA194 Loss Is due to Increased Proteasome-Mediated
Turnover
To address whether the degradation of RPA194 relates to
its polyubiquitination, we performed RPA194 immunoprecipita-
tion followed by detection of conjugated ubiquitin by Western
blotting. BMH-21 treatment increased polyubiquitination of
RPA194 as detected by a polyubiquitin antibody (Figure 8A).
We then used an in vitro degradation assay to examine the
ubiquitin-dependence of RPA194 degradation (Williamson
et al., 2009). Ubiquitin, recombinant E1 and E2 enzymes, and84 Cancer Cell 25, 77–90, January 13, 2014 ª2014 Elsevier Inc.BMH-21-treated cellular lysate as
source of E3-ligase were mixed to
assess the degradation of in vitro-trans-
lated RPA194. RPA194 was degraded
only in the presence of a fully com-
plemented ubiquitination reaction, and
the degradation was inhibited by
MG132 (Figures 8B, 8C, and S7A).
Furthermore, we detected slower mig-rating forms of in vitro-translated RPA194, suggesting its poly-
ubiquitination (Figure 8B).
Lastly, we assessed whether deubiquitinating (DUB) enzymes
were able to rescue RPA194 degradation. We ectopically
expressed a nucleolar DUB (USP36) and as comparison a nucle-
oplasmic DUB, HAUSP (USP7; Endo et al., 2009). Overexpres-
sion of USP36 effectively blocked RPA194 degradation, while
that of HAUSP did not (Figures 8D and 8E). These results show
that BMH-21 activates a process that leads to RPA194 degrada-
tion in an ubiquitin-proteasome-dependent manner.
Intriguingly, the large subunit of RNA Pol II, Rpb1, undergoes
ubiquitination and degradation in response to stalled Pol II tran-
scription complexes (Wilson et al., 2013). However, Rpb1 was
Figure 7. Inhibition of RPA194 Degradation
Does Not Rescue Transcription
(A and B) A375 cells were pretreated with MG132
(10 mM) or lactacystin (2 mM) for 30 min and BMH-
21 (1 mM) was added for 3 hr. (A) Confocal
microscopy, (B) western blotting.
(C and D) Inhibition of RPA194 degradation does
not rescue transcription. A375 cells were treated
with BMH-21 for the indicated times (C) or for 3 hr
(D). Cells were cotreated with MG132 as shown.
Pol I transcription was measured with 3H-uridine
metabolic labeling (C) or FUrd (D) for 1 hr.
Scale bars, 10 mm. See also Figure S6.
Cancer Cell
Pol I Targeting by a Small Molecule Compoundunaffected by BMH-21 treatment (Figure 8F). Furthermore, cell
stress that causes Rpb1 degradation, UV radiation, did not affect
RPA194 expression (Figures 8G and 8H). These findings suggest
differential sensing of stalled Pol I and II complexes, and activa-
tion of distinct degradation pathways.
To ask whether other drugs with known off-target effects
on Pol I transcription have similar activities, we analyzed their
effects on RPA194. Topoisomerase I and II poisons (Burger
et al., 2010) and a recently described inhibitor of Pol I preinitiation
complex formation (Drygin et al., 2011) caused RPA194 nucle-
olar cap formation but did not reduce its expression (Figures
S7B, S7D, and S7E) indicating that the decrease of RPA194
was selective for BMH-21. Furthermore, all-cause prominent
DNA damage, which may lead to less favorable tolerance
(Figures S7C and S7E). Interestingly, ActD, which is proposed
to inhibit Pol I by GpC-binding, did not reduce RPA194 expres-
sion (Figures S7B and S7D). Moreover, a sequential treatment
of cells with ActD, followed by consequent addition of BMH-21
showed that BMH-21 was still capable of activating RPA194
degradation (Figure S7F). Comparison of their GI50 profiles in
the NCI60 data set indicated that their therapeutic effects were
dissimilar (Figure S7G). Hence the effect of BMH-21 on Pol I is
distinct fromActD, the known Pol I targeting andGC-rich binding
drug, and from those with demonstrated off-target effects to-
ward Pol I.
DISCUSSION
Here, we have studied the antitumorigenic potential of a
small molecule, BMH-21, and provide detailed evidence of its
mechanism of action. We show that BMH-21 acts by binding
to GC-rich DNA, particularly to rDNA, inhibits Pol I transcription
and activates degradation of Pol I catalytic subunit RPA194.Cancer Cell 25, 77–9This work is fundamental in several
ways. It identifies first, antitumorigenic
activity of a class of small molecules;
and second, a potential cancer therapeu-
tic target, RPA194. Third, it establishes
that Pol I, through regulation of RPA194,
is controlled by the proteasome activity
in human cancer cells during transcrip-
tion stress. Overall, these results provide
strong support that Pol I is a rational and
tractable target for cancer therapeutics.BMH-21 is an unconventional DNA intercalator because it
does not appear to activate DNA damage signaling. Based on
the molecular modeling, the protonated BMH-21 stacks flatly
between the DNA bases, contacts DNA phosphate backbone
with widening of the helix, but lacks interactions with the DNA
bases, major or minor grooves. In contrast, BMH-21a1, devoid
of the protonated N-group, lacked interaction with the DNA
phosphate backbone. Although these predictions need to be
confirmed by further structural analyses, this structural charac-
teristic was critical for the BMH-21 biological activity. As the
activity of BMH-21 is reversible, it is unlikely that it interacts
covalently with DNA or traps chromatin remodeling or DNA
unwinding enzymes in inactive states. The low toxicity in normal
cells and good tolerance in mice were promising. However, its
transitioning toward clinical trials will need further toxicological
testing. In general, very few non-DNA damaging intercalators
have been recognized or explored for their cancer therapeutic
potential. These include curaxin, a small molecule that traps
the FACT chromatin modeling complex during transcription
elongation (Gasparian et al., 2011), and the dual activity auto-
phagy inhibitor and ATM activator chloroquine (Maclean et al.,
2008).
We show here that BMH-21 has binding preference to GC-rich
DNA, and that it binds rDNA in a highly GC-content dependent
manner. The extremely high transcription rate of rDNA is
supported by the open chromatin conformation and nucleo-
some-deplete nature of the active genes (Merz et al., 2008; Witt-
ner et al., 2011). The high rates of transcription are buffered by
the interspersed inactive gene repeats, which protect against
rDNA genetic instability (Ide et al., 2010). This ‘‘nakedness’’ of
active rDNA may facilitate the intercalation of BMH-21. The
GC-dependent binding of BMH-21 in vitro to the rDNA gene
does not exclude the possibility that BMH-21 binds also to other0, January 13, 2014 ª2014 Elsevier Inc. 85
Figure 8. BMH-21 Causes Proteasome-Mediated Degradation of RPA194
(A) RPA194 was immunoprecipitated from A375 cell lysates following the indicated treatments, and conjugated ubiquitin (right panel) and input RPA194 (left
panel) were detected.
(B and C) In vitro degradation assay. In vitro translated RPA194-HA was incubated with BMH-21-treated cell extract and ubiquitination reaction mixture with or
without MG132 (MG), and RPA194-HA was detected. Asterisks indicated high-molecular weight bands. (C) Quantification of RPA194-HA. The mean (n = 4) and
SD are shown.
(legend continued on next page)
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analysis, BMH-21 did not cause universal inhibition of Pol II-
driven transcription (Peltonen et al., 2010) and did not affect
the expression of Rpb1, the Pol II large subunit. However, these
findings do not rule out the ability of BMH-21 to intercalate to
also genomic DNA, in addition to rDNA, or that such binding
has relevance to its cellular responses.
Deregulation of rRNA synthesis is one of the most frequent
underlying features of malignant cells. This results from over-
activation of rRNA transcription rate, and is stimulated by the
most common oncogenic drivers in cancers. There is substantial
evidence that many oncogenes and signaling pathways, such as
Myc, Akt, and ERK control Pol I transcription by promoting the
preinitiation complex assembly, upregulating the levels of Pol I
specific factors and nucleolar proteins or by affecting their
post-translational modifications (Grummt, 2010). These findings
suggest that their specific Pol II-driven programs need to be
matched by upregulation of Pol I. Conversely, the frequent inac-
tivation of Pol I repressing tumor suppressors suggest a perpet-
ual loss of control of Pol I transcription rate in cancers. Hence, Pol
I transcription represents a key convergence point of deregulated
cancer cell activity, and addiction of cancer cells to this trait.
Pol I transcription is sensitive to extracellular cues. The loss
of positive signaling (starvation, nutrient stress) decreases
transcription rates, and the polymerase remains poised for rapid
resumption. BMH-21 led to rapid and profound repression of
Pol I transcription asmeasured by synthesis of nascent nucleolar
rRNA and the 47S rRNA precursor. The rapid segregation of the
nucleolus and delocalization of nucleolar proteins indicated that
Pol I transcription was blocked, and was akin to ActD and UV-
type transcription stress-induced changes (Andersen et al.,
2005; Hernandez-Verdun, 2006; Moore et al., 2011). Given the
capabilities of many ribosomal and nucleolar proteins to support
p53 functions (Kurki et al., 2004; Zhang and Lu, 2009), these
findings are fully consistent with the nongenotoxic activation of
p53 due to ribosomal stress, and the discovery of the molecule
in a screen for p53 pathway activation (Peltonen et al., 2010).
Transcription of active rDNA genes is determined by priming
the assembly of the preinitiation complex on rDNA. Pol I
holocomplex proteins have been considered stable once
assembled on rDNA.We found that BMH-21 caused unexpected
degradation of RPA194. The degradation was selective to the
Pol I catalytic subunit and did not involve the linker subunit
RPA43, PAF53, or the Pol I specific transcription factor TIF-IA,
preinitiation complex protein TAFI110, or UBF. RPA194 degra-
dation was mediated by the ubiquitin-proteasome system and
was marked by a decrease in RPA194 half-life, RPA194 ubiquiti-
nation in vitro, and in vivo, and its rescue by overexpression of
USP36 and inhibition of the proteasome activity. Concomitantly,
we observed loss of RPA194 and RPA135 binding to chromatin
along with that of UBF. Collectively, these results indicate that(D and E) U2OS cells were transfected with USP36-Myc or HAUSP-FLAG plasmi
antibodies. Expression of RPA194 (red) and USP36-Myc (green) are shown. Arrow
The average (n = 2 experiments, each with >100 cells) and SD are shown. ns, no
(F) A375 cells were treated with BMH-21 (1 mM) for 3 hr followed by western blo
(G andH) Effect of UVC radiation onRPA194.Western blotting of HeLa cells (G) an
bar, 10 mm.
See also Figure S7.the compound activates a process that results in ubiquitin-pro-
teasome-dependent degradation of RPA194.
The rapid kinetics of Pol I inhibition, which takes place before
RPA194 degradation, and inhibition of transcription by BMH-21
evenwhen RPA194 degradation is blocked indicate that RPA194
degradation is not the primary event that leads to transcription
inhibition. We propose that transcription inhibition results from
intercalation of BMH-21 with rDNA, and the ensuing transcrip-
tion blocks. Transcription inhibition and nucleolar segregation
because of transcription blocks was observed in all cells, and
yet, some cancer cell lines were resistant to BMH-21 anticancer
activity and retained RPA194 expression. The reasons for the
differential responses of the cancer cell lines are not clear.
RPA194 degradation may depend on cell-intrinsic factors,
including expression of the UPS-components involved and path-
ways that lead to their activation. The observation that higher
transcription rates moderately associated with the ability of
BMH-21 to reduce cell viability and the extent at which rRNA
synthesis was inhibited suggests that RPA194 degradation
may also be initiated in the cells differentially depending on the
extent of transcription blocks, transcription rates, and BMH-21
intercalation. It is possible that the inability of the cells to bypass
these transcription blocks and the ensuing RPA194 degradation
are the precipitating factors for loss of viability—and that this
response may vary based on dependency of the cells on Pol I
transcription. Regardless, the degradation of the catalytic
subunit and its dissociation from rDNA enforces profound inhibi-
tion of rRNA synthesis difficult to compensate e.g. by activation
of silent rDNA genes. The pathways sensing the loss of RPA194
need to be addressed in further studies. Cancer cell lines may
have inherent differences in their dependency of Pol I transcrip-
tion also due to their translational needs. These aspects are
relevant from a therapeutic standpoint and the possible use of
combination therapies targeting multiple pathways affecting
both transcription and translation.
Recently, the yeast homolog of RPA194 (Rpa190) was found
to be deubiquitinated by the yeast USP36 homolog, Ubp10,
and Ubp10 was shown to be important for Rpa190 stability,
rRNA synthesis and normal growth in yeast (Richardson et al.,
2012). We did not observe RPA194 degradation by DNA
damaging agents UV or IR suggesting that RPA194 degradation
is not instigated by generic transcription stress or DNA damage
(Moore et al., 2011). Loss of RPA194 may reflect a ’’checkpoint’’
where Pol I becomes arrested on the rDNA and which needs to
be resolved by degradation of the polymerase complex. This
resembles resolution of Pol II arrested during persisting tran-
scription blocks (Wilson et al., 2013). It is noteworthy that several
commonly used chemotherapeutic agents, including topoisom-
erase I and II poisons also inhibit Pol I due to their requisite activ-
ities for rDNA unwinding (Burger et al., 2010; French et al., 2011).
Further, 5-fluorouracil inhibits precursor rRNA processingds, treated with BMH-21 for 3 hr and costained for RPA194 and respective tag
head, nucleolar cap. (E) The percentage of RPA194-positive cells was counted.
nsignificant; **p < 0.01; ***p < 0.001. Scale bar, 10 mm.
tting for Pol II subunit Rpb1, RPA194, and NCL.
d immunofluorescence analysis (H) of A375 cells 3 hr after UVC treatment. Scale
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apeutics affect rRNA biogenesis that may contribute to their
anticancer activities. However, their uses are not monitored for
their potential therapeutic activity against rRNA biogenesis.
Significantly, we observed that none of the known inhibitors of
rRNA synthesis induced RPA194 degradation, suggesting that
BMH-21-mediated inhibition of Pol I is mechanistically distinct
from, e.g., ActD, topoisomerase poisons and the recently
described CX-compound (Drygin et al., 2011). This suggests
that activation of RPA194 degradation represents a unique
mechanism to switch off Pol I.
EXPERIMENTAL PROCEDURES
Cells and Plasmids
Cells were obtained from American Type Culture Collection and maintained as
detailed in the Supplemental Experimental Procedures. Human USP36-myc
was obtained from Origene and pCIneo-HAUSP-Flag was kindly provided
by Dr. B. Vogelstein (Johns Hopkins University). Human Pol I promoter plasmid
pHrP2 was kindly provided by Dr. I. Grummt (DKFZ). RPA194-HA was
constructed by cloning full-length human RPA194 in pCR-4-TOPO-RPA194
(Invitrogen) to pCMV6-AC-HA-His vector (Origene) to yield pRPA194-HA.
12H-Benzo[g]pyrido[2,1-b]quinazoline-4-carboxamide, N-[2(dimethylamino)
ethyl]-12-oxo (BMH-21) was obtained from ChemDiv, verified for purity using
liquid chromatography/mass spectrometry, and 1H-NMR.
FID Assay
FID assay was conducted as in Tse and Boger, 2005. Deoxyoligonucleotide
DNA hairpins containing an eight-bp stem region with randomDNA sequences
or human rDNA sequences (GenBank ID U13369) were purchased from
Sigma-Aldrich. EtBr (6 mM) was added to each well in sodium acetate buffer
(35 mM NaOAc, 162.8 mM NaCl, 1.75 mM EDTA, pH 5.0), followed by hairpin
DNA (1.5 mM), and 2 mM BMH-21 in sodium acetate buffer containing 2%
DMSO. For each experiment, the ratio of EtBr to hairpin DNA was adjusted
to 1 molar equivalent EtBr per 2 DNA base pairs. The 0% control wells con-
tained neither hairpin DNA nor BMH-21, while 100% control wells contained
hairpin DNA but no BMH-21. All assays were conducted in triplicate.
Molecular Modeling
Molecular docking of the compounds to DNA hexamer d(CGATCG)2, Protein
Data Bank ID 1Z3F was performed with AutoDock 4.2 software (Trott and
Olson, 2010) using the Lamarckian Genetic Algorithm to find the most suitable
solution or best binding position for the ligand. The initial docking parameters
consisted of 25 runs, maximum energy evaluations of 5 3 107, maximum of
27,000 generations, and 50 individuals per run.
Chromatin Immunoprecipitation
A375 cells (1 3 107) were fixed with 1% formaldehyde, lysed, and chromatin
was extracted essentially as in Denissov et al., 2011. All buffers were supple-
mented with 13 protease inhibitor cocktail (Sigma). Chromatin was sheared to
500–1,000 bp. Each IP was conducted using 100 mg DNA, 5 mg antibody, and
collected using secondary antibody-coupled Dynabeads (Invitrogen). DNA
was purified with ChIP DNA Clean and Concentrator kit (Zymo Research),
and eluted to 100 ml. qPCR was conducted using 2 ml of elute in 10 ml reaction,
using a final concentration of primers at 200 nM on ABI Prism7900. Primer se-
quences are listed in the Supplemental Experimental Procedures.
rRNA Synthesis Assays
Cells were labeled with 1 mM 5-FUrd (Sigma) using hypotonic shift and fixed
with ice-cold methanol and acetone. Cells were blocked in 3% BSA and
FUrd was detected using anti-5-BrdU antibody. DNA was stained with DAPI.
Alternatively, cells were labeled with ethynyl-uridine (EU) and processed
according to the Click-IT protocol (Invitrogen). The analysis of de novo synthe-
sized rRNA was according to Pestov et al., 2008. Cells were labeled with [5,
6-3H]-uridine (Perkin Elmer) at 2–3 mCi/ml. Total RNAwas isolated using Nucle-
oSpin RNAII Total RNA isolation kit (Macherey-Nagel). Three to five micro-88 Cancer Cell 25, 77–90, January 13, 2014 ª2014 Elsevier Inc.grams of total RNA was separated on a 0.8% agarose-formaldehyde gel
and total 18S rRNA was detected for loading control. RNA was transferred
to Hybond-N+ filter (Amersham) and crosslinked. The membrane was sprayed
using Enhancer (Perkin Elmer) and exposed to film.
In Vitro Pol I Transcription Assay
In vitro Pol I transcription assay was conducted as in Mayer et al., 2004. The
reaction mixtures contained 500 ng of template DNA containing Pol I promoter
at 347 to +385 (pHrP2/EcoRI), HeLa nuclear extract, 10 mM HEPES-KOH
(pH 8.0), 0.1 mM EDTA, 10 mM MgCl2, 300 mM KCl, 10 mM creatine phos-
phate, 12.5% (v/v) glycerol, and 0.66 mM each of ATP, GTP, UTP, and CTP.
After incubation for 2 hr at 30C, RNA was extracted, and the rRNA product
was amplified using PCR primers for 50ETS rRNA located at +2 (forward), +82
(reverse), analyzed in 8% polyacrylamide gel, and stained using SYBR Gold.
RNA Interference
U2OS cells were transfected with control siRNA duplex or specific siRNAs
(10 nM) using Lipofectamine RNAiMAX (Invitrogen) and incubated for 48 hr.
The following siRNAs were used: POLR1A si403, si405, and control siRNA
(Ambion).
In Vitro Degradation Assay
In vitro degradation of RPA194 was as in Williamson et al., 2009 with slight
modifications. Cells were treated with BMH-21 for 3 hr and extracts were
prepared in SB-buffer (20 mM HEPES pH 7.5, 1.5 mM MgCl2, 5 mM KCl,
1 mM dithiothreitol, protease inhibitors [Roche], 15 mM creatine phosphate,
2 mM ATP). Reactions were carried out in a mix containing human recombi-
nant E1 (32 ng/ml), UbcH5c (50 ng/ml), UbcH10 (10 ng/ml), ubiquitin
(50 ng/ml), Ub-aldehyde, and supplemented with 5 mM ATP. Reactions
were initiated by addition of in vitro translated pRPA194-HA (TNT Coupled
Reticulocyte Lysate System; Promega) and incubated for 90–120 min at
30C. MG132 was used at 85 mM when indicated.
Mouse Xenograft Studies
All mouse studies were conducted according to the animal experimentation
permits of Animal Care and Use Committee at Johns Hopkins University and
the Institutional Animal Care and Use Committee at University of Maryland
Baltimore County (MO12M141, MO12M325, and CB010631215, respectively).
Pharmacokinetic and toxicity studies are detailed in the Supplemental Exper-
imental Procedures. For tumor xenograft experiments, A375 (3 3 106) or
HCT116 (2 3 106) cells were injected in 0.1 ml PBS to the flanks of 6-week-
old athymic NCr nu/nu mice, and the tumors were allowed to establish until
they reached 90–120 mm3. Mice were randomized to respective treatment
groups (mock, BMH-21 25 mg/kg and BMH-21 50 mg/kg). Mock treatments
consisted of phosphate-citrate buffer (pH 6.0). Treatments were administered
intraperitoneally on a cycle 6 days on, 1 day off (A375) or daily (HCT116). Tumor
weight (TW) was calculated by measuring the tumor diameter with a caliper
and using the formula: TW = (L 3 W2)/2 where L is the tumor length and W is
the tumor width. Tumor growth ratios were calculated as Dtumor weight
(median) of treated group/Dtumor weight (median) control group.
Statistical Analysis
Values were calculated using Student’s two-tailed t test and statistical signif-
icance of tumor growth was assessed using two-way ANOVA. The p values are
expressed as follows: ns, nonsignificant; *p < 0.05; **p < 0.01; ***p < 0.001; and
****p < 0.0001.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and seven figures and can be found with this article online at http://dx.doi.
org/10.1016/j.ccr.2013.12.009.
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